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EDITORIAL REVIEW
Primary hyperoxaluria: Therapeutic strategies for the 90's
Primary hyperoxaluria type 1 (PH 1) is an orphan disease with
a host of unrecognized relatives, including those patients with
idiopathic kidney stones. Excessive urinary oxalate combines
with urinary calcium to form stone in the urinary tract, neph-
rocalcinosis. The more fortunate patients present early with
clinically recognized renal stones, so that a diagnosis can be
made early and treatment instituted. Even when asymptomatic,
nephrocalcinosis causes diminished renal function, resulting in
increased oxalate excretion by the remaining nephrons, and a
cycle leading to inevitable renal failure. The rarity of PHI leads
to frequently disastrous delay in diagnosis, resulting in naive
medical treatment. This often includes routine cadavaric renal
transplantation, with rapid recurrence of nephrocalcinosis by a
pooi of accumulated oxalate that adds to endogenous produc-
tion. This leads to destruction of the transplanted kidney, as
well as the disastrous medical complications of systemic oxalo-
sis. With special precautions, renal transplantation can be
successful in selected patients, and almost all complications of
systemic oxalosis avoided.
Considered as a usually fatal metabolic defect of liver metab-
olism, without specific treatment available, PH1 could provide
an opportunity for a complete cure by hepatic transplantation,
necessarily coupled with renal transplantation. Our consider-
ation of therapeutic options requires that an individualized
strategy consider the patient as well as the disease. The
integration of recent knowledge of the molecular biology and
mechanisms of PHI with conventional clinical judgment is a
challenge. The algorithms of diagnosis and treatment are trans-
ferable to some of the more common nephrologic and urologic
problems.
Metabolic pathways of oxalate generation have been well
reviewed recently in a Symposium [1] appropriately dedicated
to the inspired long-term contributions of Sir Richard Watts,
and a comprehensive update [2] of the classic reviews by other
leaders in the field, Williams and Smith [3, 4]. These excellent
clinical summaries noted the dismal outlook for PH 1 after renal
failure had ensued. As of 1983, renal transplantation was looked
upon as hopeless, and therefore contraindicated [4]. However,
several treatment regimens for PH1 were explored, providing
the encouragement for more recent efforts, many well-reviewed
in the symposium edited by Rose [51. The purpose of this
review is to provide algorithms for the diagnosis and manage-
ment of PH1 that consider the current state of our knowledge
and may increase that knowledge, both of PH1 and related
states of nephrolithiasis. It should be noted that Type II primary
hyperoxaluria (McKusick #26000) is due to deficiency of
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D-glycerate dehydrogenase, or glyoxylate reductase, a cyto-
solic enzyme found in many tissues, accompanied by increased
oxalate and L-glycerate excretion. Its rarity and probable need
for similar management justify its exclusion from this review. A
third type of (possibly primary) hyperoxaluria, mild metabolic
hyperoxaluria [61, due to hyperabsorption without apparent
primary gastrointestinal disease, may also be genetic.
Incidence and natural course
The rarity of PHI makes both incidence and natural course
difficult to estimate. Patients have been recognized by recurrent
nephrolithiasis, by dense nephrocalcinosis after renal failure
has appeared, and by the investigation of asymptomatic family
members of known cases. The apparent incidence and natural
course may be more related to physician awareness than to the
intrinsic disease. Unfortunately, some patients are now recog-
nized late, even after renal transplantation, by the appearance
of recurrent renal insufficiency [7].
At the Mayo Clinic, 13 patients without renal failure were
followed over 10 to 20 years [81. In London (with a high level
of awareness of PHI) over 20 years, 16 children were recog-
nized 191. five by the silent onset of renal failure. In that
Pediatric center, the incidence was similar to that of cystinosis
or distal renal tubular acidosis. In the European Dialysis and
Transplant Association registry [101, 221 (mostly adult) pa-
tients with hyperoxaluria and end-stage renal failure were
recognized over 1971 to 1987, nearly 15 per year since 1976, in
a population of about 500 million. In the three years since its
inception, the North American Pediatric Transplant Coopera-
tive Study (APTCS) has recorded 15 renal transplants in II
patients with PHI. In our practice, between 1975 and the
present, between referrals for transplantation and enquiries for
guidance (now channeled through the Oxalosis/Hyperoxaluria
Foundation), almost 50 patients have been recognized in the
U.S. Since the molecular mechanism was recognized, and
enzymatic diagnosis sought over the past three years, liver
biopsies of 59 patients world-wide with PHI have been exam-
ined at the MRC Clinical Research Center [111.
If one-third of patients initially present with completely silent
renal failure, there may still be 40 to 50 patients per year in the
U.S. whose diagnosis can be made earlier and "inevitable"
renal failure avoided. It is then reasonable to estimate that 10 to
15 new patients per year will be recognized with end-stage renal
failure due to PH1 in the U.S., and two to three times this
number in Europe. There may be over twice this number never
recognized. PH! is a rare identifiable cause for the numerous
patients with nephrolithiasis (20 per 10,000 population per year
[121). Therefore the yield of screening will be low. However,
the genetic predisposition to hyperoxaluria may be far more
frequent (see below), and may make genetic screening impor-
tant in the future.
The diagnostic (Fig. 1) and therapeutic (Fig. 2) algorithms for
PH1 will be addressed according to the sequence of decisions
under Presenting Findings, and appropriate Diagnostic Ap-
proach (in Fig. 1), or Therapeutic Decisions (in Fig. 2).
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Nephrocalcinosis
Renal function
decreased, > 40
Renal insufficiency
GFR < 40 mI/mm
Renal failure
GFR <20
Prolonged renal failure
Nephrolithiasis—Diagnosis
A clinical presentation of stone disease occurs when precip-
itable substances achieve supersaturation in urine, when "seed-
ing" (nucleation) of crystal occurs, and when crystal growth is
uninhibited. Extensive studies of urinary composition have
failed to assign simple causes for "idiopathic" (calcium oxalate)
nephrolithiasis. The formal position paper published by the
NIADDK [12] suggests that appropriate investigations include
careful attention to medical history, renal anatomy, stone
composition and urinary composition. A landmark in nephroli-
thiasis investigation was the understanding of ionic equilibrium
in urine by multifactorial analysis [131. The imbalance between
ionic supersaturation and the natural inhibitors of crystal for-
mation and growth [13, 14] remains a complex but reasonable
explanation for nephrolithiasis when gross hyperoxaluria is not
present. The combination of relative hypercalciuria and relative
hypocituria [15] seems to best identify stone risk, although
numerous other factors, including the concentrations of poly-
phosphates [16], Mg, and organic inhibitors of calcium oxalate
crystal growth, such as nephrocalcin [17], all can contribute to
the final tendency to form stones. Hyperoxaluria is the factor
long recognized as predisposing to stone formation [12].
The appearance of a first kidney stone in adult patients
requires screening for hypercalciuria, by at least measuring a
random urine calcium/creatinine ratio (normal <0.2 mg/mg),
and performing renal ultrasonography to rule out further neph-
rolithiasis or diffuse nephrocalcinosis.
For repeated stone formation or even a first stone in a child,
in addition to renal ultrasound, excretory urogram (with tomog-
raphy) can help to rule out residual nephrocalcinosis. It is
important to carefully collect a (timed) urine for composition, as
a urine "stone" panel (creatinine, Ca, P, Mg, urate, Na, K,
citrate), as well as for plasma levels of Ca, P, alkaline phos-
phatase, uric acid, and electrolytes (including bicarbonate for
renal acidosis).
Increased urine Ca (over 4 mg/kg/day), presumptive of
hypercalciuria, should suggest retesting after calcium restric-
tion. If stone disease is not explained by hypercalciuria or
hyperuricosuria, urine aliquots that have been acidified and
frozen should be submitted for oxalate analysis.
Diagnosis of hyperoxaluria in patients with clinical
nephrolithiasis
The diagnosis of hyperoxaluria requires both a reliable assay
method and knowledge of normal oxalate excretion. Accurate
measurement may require the use of a relatively few, well-
standardized laboratories, and meticulous attention to the de-
tails of sample collection and handling, which can make the
difference between values considered normal or hyperoxaluric:
When six methods were compared in a collaborative study [18]
of chromatographic, enzymatic, GC, ion exchange and HPLC
assays for oxalate, mean concentrations were similar, but high
variability was found within and between laboratories (8 to
60%). A collaborative standardization effort in the United
Kingdom [19] found a similarly high variability. The most
widely used method, the Sigma enzymatic kit, was found to
require as ascorbate removal method to avoid a positive bias,
but this even increased the variability. The least variability
was demonstrated by two specialized laboratories utilizing
immobilized oxalate oxidase [20], whose cost-effectiveness
requires the performance of large numbers of samples. The
I Diagnostic Algorithm for PHi
Presenting Finding jJ L
Stone disease I I
ii
Adult, first stone IT
Diagnostic Approach
Urine Ca/Crest (nI < 0.2)
Child or repeat stone
Hyperoxaluria
stone or asymptomatic iL
Oxalate> 45 mg/d adult
Ox/Crest 0.1 mg/mg child
0.3 g/mg infant
al ultrasound for density -
urine stone panel:
(NL)
Plasma Ca, P. PTHtUrine oxalate x 2
lofB6B6 - resistant Repeat urine oxalate (high)
Renal ultrasound density (increased)
reGFR
Liver biopsy forAGT 1
Bone marrow for oxalate
Fig. 1. Diagnostic algorithm for primary
hyperoxaluria (PHI), by presenting finding
leading to (solid arrows) diagnostic approach
which in turn lead to (open arrows, R to L)
presumptive diagnosis.
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Fig. 2. Therapeutic algorithm for PHi, in which
presenting findings lead to appropriate (closed arrows)
or alternate (open arrows) therapeutic decisions.
importance of sample handling is evident in the dramatic loss
(by precipitation) of Ca and oxalate with simple refrigeration,
and the special need for acidification to <pH 1.5 for both
stability and dissociation of complexed oxalate [211.
The upper limit of normal daily excretion of oxalate for adults
is considered to be less than 0.50 mmols (45 mg). In infants, it
is difficult to obtain timed urines. Leumann, Dietl and Mataso-
vie [22] have recently reviewed normals using a well-controlled
enzymatic method, and shown that in infants, random urine
specimens differ little from first morning specimens. Related to
urine creatinine, oxalate excretion was 185 mM/M (range: 84 to
356), or 0.148 in mg/mg (range: 0.067 to 0.285), for infants under
six months. For children over one year, oxalate/creatinine was
26 mM/M (range: 13 to 79), or 0.021 mg/mg (range: 0.01 to
0.063). By age 9, the 2 SD limit was below 60 mM/M, or 0.05
mg/mg creatinine. Morgenstern et al [23] studied normal infants
through eight months of age, using a similar immobilized
enzyme technique, and found a normal mean oxalate/creatinine
ratio of 100 mM/M (range: 25 to 388) or 0.08 mg/mg (range: 0.020
to 0.31). These normal values imply that a 10 kg infant could
excrete as much as 20 mg oxalate per day, or over 100 mg/i .73
m2. Thus normals in children need further definition, but these
guidelines can be adopted: Suspicious urinary oxalate/creati-
nine values, by any proven method, are >0.3 mg (340 mM/M) in
infants, >0.1 mg/mg (100 mM/M) in children over one year of
age, or >0.05 mg/mg (60 mM/M) over age five. Values exceeding
these limits require retesting a timed specimen.
Before inclusion or exclusion of a diagnosis of hyperoxaluria,
it is best to submit the two carefully supervised, timed urine
collections to an active laboratory whose assay variability is
known. Should results be borderline or elevated (>45 mg/day in
adults), repeated analysis of samples should be performed,
perhaps by a second laboratory.
The diagnosis of PHi has traditionally required demonstrat-
ing markedly elevated urinary excretion of both oxalate and
glycollate, in the absence of other definable causes, such as
primary bowel disease, or massive intake of oxalate (such as,
rhubarb gluttony) or a potential precursor, such as ascorbic acid
or ethylene glycol [24]. Because at least one-third of proven
eases of PHI do not have glycollic aciduria [ill, the definition
should be considered tentative without an enzymatic diagnosis,
as can be performed at the MRC Clinical Research Center [11].
Primary hyperoxaluria type 1: The enzymatic and molecular
defect
PHI (McKusick #25990) is due to deficient hepatic peroxi-
somal alanine :glyoxylate aminotransferase (AGT). Pyridoxine
is a cofactor. In a study of peroxisomal enzymes in disease,
Nakatani et al [25] showed that AGT was only mildly changed
in chronic liver cirrhosis. In 1986, Danpure and Jennings [26]
showed the absence of AGT in PH!, and defined it as a
peroxisomal disorder. The prior explanation of PHi as a
cytosolic oxoglutarate:glyoxalate carboligase deficiency was
probably based upon mitochondrial damage in the techniques
used [27].
While AGT was found in the peroxisomal fraction of liver,
ultrastructural examination showed only a mild decrease in size
and number of peroxisomes [28, 29], compared to more drastic
changes in generalized peroxisomal diseases [30]. Subcellular
Increase fluid intake
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fractionation of residual AGT activity in four cases of PH!
showed a complete deficiency of peroxisomal AGT and its
(diminished) presence in a mitochondnal fraction, compared to
controls [31]. AGT protein was then localized by protein A/gold
immunocytochemistry to peroxisomes in normals [32]. An
enzyme displacement was then shown, by density gradient
centrifugation and protein A-gold immunocytochemistry, show-
ing AGT in mitochondria [33] (Fig. 3). These patients were
more severely affected than residual total AGT activity would
imply, and were best explained by a trafficking defect of the
AGT, (t-PH1) whereby residual enzyme activity was not posi-
tioned in the peroxisome to detoxify glyoxylate where it was
generated.
A more sensitive radiochemical AGT assay was developed
[34] and allowed the enzymatic diagnosis of PHi on (100 mg)
liver biopsy tissue [351, which normally has AGT activity of 4 to
8 mollhr/mg protein [11]. Of the 59 patients studied, almost
one-third had significant AGT activity, and those whose ultra-
structure was examined had displacement of immunolocalized
activity to mitochondria, the t-PH1 [11]. Heterozygotes with
circa 30% enzyme activity on liver biopsy have AGT present in
the normal peroxisomal locus, available to allow glyoxylate
detoxification and normal oxalate excretion.
A distinctively "malignant" course has been implied for
infantile hyperoxaluria [36]. Leumann, Niederweiser and Fan-
coni [37] point out the extreme rapidity with which nephrocal-
cinosis can occur. How the normally higher oxalate excretion of
infants relates to those patients with infantile oxalosis is not yet
clear. The degree of enzyme activity does not seem to deter-
mine the onset or severity of PHi, in that few of the patients
with completely absent AGT enzyme activity had infantile
onset [11]. One patient with absent AGT activity was com-
pletely asymptomatic until age 55, developing renal failure only
10 years later [11]. Therefore, the degree of hyperoxaluria, but
not necessarily the degree of enzyme deficiency, may explain
clinical severity.
The asymptomatic hyperoxaluric patient, perhaps a relative
of a known PHi patient, needs to be evaluated and treated
exactly as the hyperoxaluric patient with isolated stone disease,
suffering a metabolic "malignancy" [38] that is poised to
overwhelm normal defenses without warning. While a liver
biopsy is not immediately mandatory, it is justified to verify the
enzymatic diagnosis. DNA analysis may allow this verification
at less risk when it is validated and available: The AGT cDNA
has been cloned, and partially sequenced [39]. It is only a
matter of time before the mutation(s) for PHi can be identified
in the amplified genomic DNA.
Prenatal diagnosis is a special case of the asymptomatic
patient whose diagnosis is mandatory, both for genetic coun-
seling and neonatal management. Amniotic fluid assay for
oxalate and glycollate have not provided reliable diagnoses [37],
and chorionic villi would not be expected to have AGT activity.
Prenatal liver biopsy has allowed a correct diagnosis, within the
time that pregnancy could be safely terminated [28]. Investiga-
tion of fetal liver AGT showed a normal plateau between 17 and
21 weeks gestation, at about 30% of postnatal values, with
normal localization in peroxisomes. Successful positive and
negative diagnoses were then made by fetal liver biopsy [40], as
previously proposed [41]. DNA-probe analysis may soon allow
a reliable diagnosis at less risk [39].
PHi with renal oxalate deposition
In the presence of residual stones or increased echodensity in
nephrocalcinosis, initial assessment should be made of the renal
damage that has already occurred. Renal function (as GFR) is
now most easily measured by Tc-DTPA. Because the patient
with hyperoxaluria is at grave risk of rapid progression to renal
failure, beginning treatment of documented hyperoxaluria, (as
presumptive PH1) is appropriate even without a definitive
diagnosis. The differential diagnosis is so limited for dense
nephrocalcinosis that renal biopsy is probably not essential.
Nevertheless, a liver biopsy, for AGT activity and immuno-
electron microscopy, should be performed as soon as is feasi-
ble, according to the processing protocol described by the MRC
Clinical Research Center [11].
For patients who first present with renal failure urinary
oxalate excretion may remain elevated (oxalate to creatinine
ratio >0.1 mg/mg) due to the relatively constant oxalate to
creatinine clearance ratio of 2:1 [42]. Even if total urinary
oxalate excretion were no longer elevated, the diagnosis of PHI
would be most likely suspected from dense nephrocalcinosis by
ultrasound. Any patient without a firm diagnosis of the original
cause of renal disease should have a renal ultrasonographic
study before receiving a transplant, to detect dense nephrocal-
cinosis, evoking a tentative diagnosis of PH1.
Plasma oxalate measurement
It would be helpful for the diagnosis of renal failure if the ratio
of plasma oxalate to creatinine in PHi could be easily mea-
sured, as it is undoubtedly markedly increased, reflecting of
increased synthesis [20]. Kasidas, using the immobilized enzy-
matic technique, found that the plasma oxalate/creatinine ratio
in PH1 with renal failure far exceeded that in renal failure alone.
He suggested that a ratio greater than 0.038 mM/mM (0.03
mg/mg) implied a diagnosis of PHi [20]. If systemic oxalosis is
the secondary result of plasma supersaturation, assay of the
plasma level could help to monitor the risk, and to understand
the dynamic relationship between tissue stores, plasma level
and urine concentration after renal transplantation, that proba-
bly determines the outcome.
The assay of oxalate in plasma has been plagued by even
greater problems than that in urine. The greatest problem has
been to obtain believably low normal results, comparable with
what has been accepted as a "gold standard" (in the range of
I ,CLM), derived from the plasma distribution and clearance of
isotopic '4C-oxalate. This not unreasonably assumes that
'4C-oxalate is completely exchangeable with endogenous '2C-
oxalate. Williams, Johnson and Smith first used 14C-oxalate
infusion to provide a relative estimate for oxalate clearance
[43]. This method, combined with an enzymatic method for
urine allowed a real quantitation [44], as well as estimation of
the pool size, distributed in about 30% of body weight (ECF
volume). Prenen et al [42] also used isotopic infusion, and
found a similar oxalate/creatinine clearance ratio (2.0) and
normal value in the range of <I jIM.
Thenon-isotopic methods for plasma oxalate that give suitably
low normal values [20] have been limited to enzymatic and gas
chromatographic methods. Problems of in vitro oxalogenesis
had to be overcome, especially for enzymatic methods [45].
The GC method of Wolthers and Hayer [46], and our modifi-
cations [47—49] directly identify the assayed compound. In the
extension of our GC method for urine and plasma oxalate,
;te. .4..
•1
Af
':
J I
I
S
'7
,t ' 3
r'
aa'
Scheinman: Therapy for primary hyperoxaluria 393
Fig. 3. Protein A-gold immunocytochemistty of AGT in liver biopsies. (a) Control; (b) control (obligate PHI heterozygote); (c) patient with little
or no AGT in either peroxisomes (F) or mitochondria (M); (d) patient with Trafficking Defect, having AGT only in mitochondria (M). Reprinted
from [33] with permission of Dr. Danpure.
utilizing mass spectrometry, we employed quantitation rela-
tive to a completely comparable internal standard, the stable
(nonradioactive) isotope '3C-Oxalate, allowing precise identi-
fication of both the native '2C-oxaiate and the standard. While
in urine and plasma, calibration was linear, analytical preci-
sion 6%, and plasma recovery over >90%, our normal plasma
values were surprisingly variable [49], and values greater than
we found by GC alone [47]. This seemed to result from sample
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extraction, not in vitro generation. Dilution resulted in an
increase in the specific value of native '2C-oxalate, compared
to the known '3C-oxalate. Therefore, oxalate in plasma was
bound (to some substance, for example, protein) under the
conditions of the assays that provide believably" low values
[20], and could be released by other extraction conditions.
Note that '4C isotopic infusion studies could not measure the
native oxalate per Se. '4C-isotopic oxalate recovery may be
complete precisely because it does not exchange with bound
oxalate. Therefore isotopic infusion-derived assays of plasma
oxalate and clearance probably correctly measure free oxalate
and its clearance; the non-exchangeable compartment in
plasma (and elsewhere) could serve as a pool that increases
urine oxalate excretion when renal function is normalized after
transplantation [48].
Because these methods are currently unreliable in all but a
few laboratories, diagnosis should still depend on other find-
ings.
Risk of systemic oxalosis in PHi with renal failure
Oxalosis is the systemic crystallization of calcium oxalate,
outside of the urinary system, usually following failure of the
urinary system to excrete oxalate. In PHi, oxalosis occurs
rapidly after the development of renal failure, beginning when
renal clearance of oxalate has diminished to result in supersat-
uration and precipitation. Within bone, crystalline oxalate
appears to incite the increase in bone turnover [50, 51] that may
explain oxalate bone disease [52], as well as that in other areas
such the retina [50, 53]. For the PH1 patient with renal
insufficiency a bone marrow biopsy will reveal one of the
earliest sites of systemic oxalate deposition.
For the PH! patients with renal failure, solid data has been
lacking for estimating the dynamics and risks of oxalate gener-
ation, distribution and mobilization. Our best analyses have
been derived from isotopic oxalate infusion studies: '4C oxalate
is infused, and the volume of distribution and plasma to urine
clearance ratios determined, and then the actual plasma con-
centration is derived from the chemically determined urine
concentration. The (non-urinary) disappearance of isotopic
oxalate from plasma will determine "tissue oxalate accumula-
tion rate".
In spite of assay difficulties, several studies have indicated
that tissue accumulation of oxalate will occur at a plasma
concentration over 20 M, which may occur in PH! at a GFR in
the range of 40 mI/mm, or at a plasma creatinine of approxi-
mately 2.5 mg/dl [39]. The measurement of plasma oxalate
concentration and supersaturation was (ingeniously) measured
by Worcester et al [54], by the growth of seeded crystals in
plasma, showing oxalate accretion at a plasma concentration of
>50 /LM, in patients without PH!.
Clinically, the rapid progression to ESRD, and the severe
complications of oxalosis in PHi, including destruction of the
transplanted kidney, make early diagnosis and treatment man-
ditory. All efforts should be directed to maintaining renal
function, avoiding even transient loss of renal function, and
accelerating the course of renal replacement when inevitable.
Initial therapy of PH!
Appropriate initial treatment of any stone disease is benign,
and includes an increase in fluid intake to decrease the concen-
tration of precipitable ions (Fig. 2). Both diet-resistant hyper-
calciuria and idiopathic, frequently-recurrent nephrolithiasis is
often treated with citrate or non-calciuric diuretics, such as
thiazides or metolazone.
The patient with documented hyperoxaluria, requires a func-
tional test of pyridoxine (vitamin B6) sensitivity, first at a low
[55] dose (25 mg/day) for two to three weeks, then increased to
250 mg/day if there is no measured decrease in oxalate excre-
tion. If repeated urine oxalate secretion decreases, this B6
response can tested later by cautious withdrawal of B6 for no
more than two to three weeks.
Watts has suggested that B6-sensitive or -resistant forms of
PHi may be due to genetic heterogeneity involving either
genomic deletion or affinity differences in the cofactor (B6)
binding site [56]. In a small group of pyridoxine-sensitive PHi
patients studied by liver biopsy/assay, two had the proven
mitochondrial enzyme displacement (t-PH!). It is likely that all
B6-sensitive patients will have residual enzyme activity, and
thus most likely have the t-PH1 defect. Most t-PH1 patients,
however, are not pyridoxine-sensitive [1!].
The treatment of B6-resistant hyperoxaluria initially requires
pushing urine volume to as high as 3.5 liter/day, assisted by
non-caiciuric diuretics as might serve any nephrolithiasis. A
low oxalate diet is recommended, although the amount of
oxalate derived from absorption is likely low. Drastic restric-
tion of dietary Ca could actually result in increased oxalate
absorption.
The therapy of PH 1 that historically has best precedent is
(neutral) orthophosphate, gradually increased to 0.5 to 1.5
g/day, and magnesium gluconate, I g/day, as tolerated. This
approach to treatment for PHi combined measures (Mg, phos-
phate) to inhibit crystallization. The detailed account by Smith
and Williams in 1967 [57] demonstrated the value of orthophos-
phate in nephrolithiasis, and became the basis of our reported
protocols [58, 59]. Others [60] have confirmed their studies. A
long-term follow-up of his program for PH! has been reported
[8], in which active urinary calcium oxalate stone formation was
successfully inhibited in 12 of 13 patients over a mean 12.4
years. Nevertheless, the mechanism of effect of orthophosphate
has been difficult to prove as a direct inhibition of crystal
formation and growth, and may be most useful [61] by decreas-
ing Ca absorption and therefore urine Ca. Mg and citrate both
affect calcium oxalate solubility while pyrophosphate may have
minimal effect [62]. Citrate inhibits crystal agglomeration sig-
nificantly, as does pyrophosphate in high concentrations. An
increase in urinary citrate can probably be generated by any
potassium alkali administration [63, 64], and could be a valuable
adjunct to the treatment of PH!, but its addition may further
aggravate hypocalcemia. Therefore we would add citrate only
to patients who become acidotic (even while taking neutral
phosphate) or have <1.5 mmol/day citrate excretion. There is
constant need to monitor urine Ca, plasma Ca, P, and alkaline
phosphatase for hyperparathyroidism due to the hypocaicemia
that may be induced by therapy.
The hyperoxaluric patient with established renal insufficiency
(GFR less than 40 ml/min) will almost inevitably progress
rapidly to end-stage renal failure. Not only must the diagnosis
be confirmed (liver biopsy), but early measures taken so that
the chance of successful renal replacement is not lost. The same
initial treatment measures must be instituted as before renal
failure, including maintaining maximum urine output possible
(without hypertension), and the use of thiazides, a low oxalate
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diet, and pyndoxine (250 mg/day). Treatment with orthophos-
phate would result in hyperphosphatemia and aggravated
hyperparathyroidism. Hemodialysis should then be planned
soon, to add to remaining GFR in preventing "malignant"
progression of renal failure, in preparation for (living-related)
renal transplantation, according to a protocol [58, 59] that gives
attention to the immediate risk of renal oxalate deposition.
Renal transplantation—Problems to be addressed
The history of treatment of PH! after established end-stage
renal failure has been discouraging. In preliminary data, pro-
vided by Dr. Michel Broyer [10], the European Dialysis and
Transplant Association has identified 221 patients since 1971
with renal failure due to PHi. Of 98 receiving a first renal
transplant, 79 were (known) cadavaric. Fifty-five percent of
these failed within six months, and only 17% functioned by 36
months. While the (fewer) living related transplants (none less
than 15 years of age) appeared to do better, with 61% function-
ing by one year, at three years only 23% were functioning. In
this series the results for patients on dialysis more or less than
one year did not differ.
The recurrence of nephrocalcinosis and the resultant renal
failure after renal transplantation for PHi has been, except for
scattered reports, an accepted outcome, until our series of 11
patients [48]. Our strategy was devised to address the following:
Essentially all of the problems of PHi seem to be explainable
by the hyperoxalurta. Nevertheless, the amount of hyperox-
aluria alone has not easily explained the severity of symptoms
or the rapidity of the course to renal failure. Some patients with
PH 1 had long asymptomatic courses before the onset of neph-
rolithiasis or renal failure. Once renal function was compro-
mised, the course to renal failure was extremely rapid.
The rapid recurrence of nephrocalcinosis in transplantation
has been contrasted to the prior extended course to renal failure
of the same patients. Thus renal failure or transplantation
impose a special risk.
Since patients with PH1 without renal failure have been
medically managed with decreased stone activity and stable
renal function by an exacting protocol which attended to
oxalate crystal inhibition [8], it was assumed that the early risk
of transplantation was related to the release of systemic depos-
its of oxalate. Since renal oxalate stones have been shown to
diminish in size or disappear under the "preventive" protocol,
we surmised that the systemic deposits could similarly dissolve
under non-saturating plasma conditions, but then add oxalate to
the synthetic load presented to the kidney, accelerating the
process of nephrocalcinosis. Oxalosis can even be seen in
non-hyperoxalunc patients with long-standing dialysis-depen-
dent end-stage renal failure [65]. This is caused by elevated
plasma oxalate. A large body load of oxalate may cause clinical
problems even in some non-PH1 patients, such as severe
vascular access problems [66] or post-renal failure nephrolithi-
asis [67].
Renal transplantation—The protocol
The transplant protocol [59, 60] was designed to provide an
initial compensatory advantage (aggressive pre-transplant dial-
ysis and extreme early post-transplant urinary dilution), and to
avoid any transient renal insufficiency, by early post-transplant
dialysis if needed. This essentially demanded the use of a large
living-related kidney, with least chance of initial malfunction,
using anti-lymphocyte globulin prophylaxis. A long period of
renal failure before transplant was to be avoided, as creating a
potentially insurmountable risk of added oxalate burden. The
preventive protocol was exaggerated, to add all potentially
helpful components: pyridoxine, increased urine volume, or-
thophosphate, magnesium, and diminished urine calcium (by
mild hypocalcemia and non-calciuric diuretics). The added risk
of treatment was felt justified, in view of the previously poor
prognosis.
The relatively short-term results in optimal patients who
could be given this opportunity were satisfying [59]. In contrast,
prolonged (over two years) dialysis before transplantation re-
sulted in two adult graft losses; two infants who were main-
tained on routine CAPD for >6 and 13 months, respectively,
underwent early and progressive oxalate deposition.
Watts has also utilized an aggressive protocol and showed
success with both a living related transplant and a very early
cadaver transplant [56]. He compared these with five cadavaric
failures whose recipients more routinely treated. He made the
argument for early renal transplantation in PH! [68, 69] by the
elegant use of dynamic isotopic studies. As studied in six
transplanted patients, the three with at least short-term success
had considerably lower measured plasma oxalate levels pre-
transplant. However, the measured oxalate metabolic pool and
calculated production rate pretransplant was not obviously
different in this study between the successes and the three
failures [70]. Dynamic studies have shown an increasing oxalate
metabolic pool and tissue oxalate accumulation rate in PHi
when GFR decreases below 40 mI/mm [70]. While these radio-
active techniques are unlikely to be performed in the U.S., it is
possible that non-radioactive studies can provide comparable
and even more precise data.
Small but important differences in the British strategy [69]
include the recommendation of cyclosporine instead of azothi-
oprine, on the basis of its predisposition to uretenc leaks and
wound infections [70]. We excluded cyclosporine, because of
the concern that cyclosporine nephrotoxicity might both poten-
tiate oxalate deposition, and decrease renal function. Drach-
man, Dollberg and Drukker [71] implicated cyclosporine in a
PH1 transplant failure. Cyclosponne toxicity even caused the
loss of one of Watts' early successes [70], unusual in non-
oxalate transplants. In that rejection has played an important
role in several graft losses, lower-dose cyclosporine in combi-
nation with azathioprine and anti-lymphocyte globulin [72] or
OKT3 induction may further reduce rejection, this approach
should be considered. One patient in the U.S., in whom Imuran
and cyclosporine were started one week before LRD trans-
plant, has done excellently for 1-1/2 years. One aspect of the
British strategy, the continuation of dialysis for 7 to 10 days
after a fully functioning transplant [69], is not likely to add
greatly to the renal oxalate removal of a well-functioning
kidney, shown to be as great as 800 mg in two of our patients
[47].
The patient presenting with renal failure and nephrocalcinosis
should begin immediate aggressive hemodialysis in preparation
for (living-related donor) renal transplantation. The diagnosis
should be confirmed by liver biopsy for AGT assay, and the
extent of oxalosis assessed by bone marrow and radiographic
skeletal examination. In the absence of a living donor, daily (5
to 6 times/week) high clearance (>5 mI/mm/kg) dialysis should
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continue while a cadavaric kidney is urgently sought. In that we
have no successful experience with initial cadavaric transplan-
tation, we cannot discourage the pursuit of liver and kidney
transplantation.
Liver transplantation
Liver transplant for PHi was first performed by Watts et al in
1985 [73], before the enzyme defect was clearly defined. Al-
though that patient died, there was metabolic evidence of
success. In 1987, they showed a clear success [74] and recog-
nized that normalization of oxalate excretion was likely delayed
due to its ongoing release from tissue stores.
Twenty-five to thirty liver transplants, usually accompanied
by kidney transplant, have since been performed world-wide
[11]. Of 10 known in England, seven are still alive and are
considered successful in lowering oxalate excretion [11]. The
remaining (10+) (unpublished) patients in Europe are reputed to
be doing well [11].
According to the Pitt-UNOS Liver Transplant registry [75],
three centers in the U.S. report having performed liver (and
kidney) transplant for PH!. One has been reported [76] as
successful. At another institution [77], one was successful in
normalizing oxalate excretion within three months, a second
failed, and another had transient success in reducing oxalate
excretion, before the accompanying kidney lost function from
severe rejection, and the patient died at three months from
hemorrhage. A third institution reported a third failure. A third
successful outcome occurred at a fourth institution [78] (unre-
corded in the registry). Thus three of six attempts at liver-
kidney transplant in the U.S. may be considered at least initially
successful. The Pitt-Unos Registry [79] reports that the one
year patient survival of almost 900 liver transplants in patients
less than 45 years old has been approximately 76%, from 1987
to 1988. The results of liver and kidney transplant for PH! are
likely to be worse, especially if performed rarely at any one
institution. Partial (living) liver transplantation may ultimately
be successful, if the recipient liver were removed and no longer
generating oxalate. Nevertheless, it is still likely that daily
dialysis and the renal transplant protocol even for (early)
cadavaric transplant can carry greater chance of success than
liver transplant, and at less risk to life.
Complicated problems in transplantation
For the patient with renal insufficiency following an initial
renal transplant, the appropriate management depends upon the
cause of failure. If due to surgical or other complications,
rejection, or failure to carry out a consistent protocol, repeat
renal transplant may be reasonable. Patients who have lost graft
function in PH!, while maintained on our protocol have done so
rather slowly. This course can allow early retransplantation
without the vastly increased risk of a large oxalate pool, and
therefore possibly allow successful cadaver transplantation.
In a longer-term follow-up [80] or the (original plus 1) series
[59] of pediatric patients at one institution, graft losses were
considerable. One had early technical complications (obstruc-
tion) requiring reoperation, as well as infection. Another infant,
transplanted after hemodialysis for six months, also suffered
surgical complications (ureteral leak, twice reimplanted) and
complicating bacterial and Candidal infection, as well as an
early acute rejection, with resultant early loss of graft function.
While histologic examination of tissues did not suggest that
oxalate crystals were responsible for the surgical complica-
tions, the massive urine volumes required by our protocol might
have contributed. We assume that these graft losses were
avoidable. Another graft failure occurred after 20 months, the
result of early and progressive oxalate deposition in paired
infant cadaver kidneys complicated by early ATN, rejection
and an episode of shock from pancreatic hemorrhage. A late
graft loss at 24 months was unexplained, in that function and
biopsy were good at 20 months.
Retranspiantation was a demonstrated success [80] for two
patients who lost function of their first graft. Both patients were
then retransplanted within a few months, before any secondary
deposition had occurred. Both are functioning well at over three
years. Two infant grafts at our current institution were success-
ful by function and biopsy at one year, and thereafter were
damaged by transient episodes of severe dehydration, followed
by almost immediate oxalate deposition and slowly progressive
renal failure. Another child underwent rejection and oxalate
deposition with graft loss after noncompliant discontinuation of
steroids. Refusal to consider regrafting, by physicians or par-
ents, has been the major cause of death in children with PHi.
While at least seven children still have good kidney function,
even the successful transplants are at great risk from any
transient dysfunction. It seems that we should be more encour-
aging about retransplantation.
For the patient failing renal transplantation from oxalate
deposition after a vigorous and non-compromising protocol, the
best option may be liver plus kidney transplantation, in spite of
the risks. This is not absolute, since one of the infants success-
fully regrafted [801 with kidney alone had lost a first kidney from
progressive oxalate deposition.
One of the more exciting aspects of two recorded liver
transplants [77, 81] was the ability of normalized oxalate
synthesis to allow dissolution of extensive renal oxalate depo-
sition, allowing renal functional stability [81] or even improve-
ment, without kidney retransplantation.
The patient with a long (over 6 to 12 months) course of
routinely managed renal failure, cadavaric renal transplantation
is unlikely to succeed. Two long-term dialysis patients, with
grossly evident oxalate deposits, showed initial transplant func-
tion and obvious shrinkage of deposits, accompanied by persis-
tently high oxalate excretion [581. Loss of renal transplant
function was inexorable but, surprisingly, lacked the massive
intratubular oxalate deposits we expected. An infant main-
tained on CAPD for nine months presented a similar course.
Thus we proposed a direct toxicity of the high oxalate excre-
tion, in excess of its obstructive capacity [58]. Liver plus kidney
transplantation, preceded by aggressive hemodialysis, remains
perhaps the only option. Even with successful liver plus kidney
transplantation, the retransplanted kidney could be lost, from
the massive release of oxalate from tissue stores added to
continued, albeit improving endogenous oxalate production.
Prospectives
In spite of the major difficulties in managing a usually fatal
inborn error of metabolism, and the risks of enzyme replace-
ment by liver transplantation, PH! offers a most novel and
useful model, some surprising successes, and prospectives of
benefits far more widespread than the rarity of the disease
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would suggest. The t-PH 1 defect, displacement of an enzyme to
a useless locus, suggests caution in future enzyme assays for
diagnosis, and the real possibility of detection in the apparently
asymptomatic patient by genomic analysis before catastrophic
nephrocalcinosis. The ability to manage, without curing, this
"fatal" nephrocalcinosis, by early intervention and aggressive
attention to stone-forming risks, encourages appropriate man-
agement for idiopathic nephrocalcinosis. The inborn error, in
fact, may be far more common than suspected, and require a
"provocative" test to reveal the tendency to hyperoxaluria,
which in fact is only a final pathway of several complex
metabolic processes, whose balance determines the difference
between the apparently normal person and the long-suffering
patient.
JON I. SCHEINMAN
Durham, North Carolina, USA
Notes added in proof
Another prospective on treatment of PHI has recently appeared
(WAn-S RWE: Treatment of renal failure in primary hyperoxaluria.
Nephron 56:1—5, 1990), with minor differences in approach. Also, a
review of the combined hepatic and renal transplants from England,
Rochester, MN, and Ann Arbor, MI has shown both its potential
benefits and considerable risks (WATTS RWE, MORGAN SH, DANPURE
CJ, PURKISS P. CALNE RY, ROLLES K, BAKER LRI, MUNSELL MA,
SMITH LN, MERION RM, LUCEY MR: Combined hepatic and renal
transplantation in primary hyperoxaluria type I: Clinical report of nine
cases. Am J Med 90:179—188, 1991).
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